The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery

Kenta Izumi, Kiyoyuki Eishi, Shiro Yamachika, Kouji Hashizume, Seiichi Tada, Kentaro Yamane, Hideaki Takai, Kazuyoshi Tanigawa, Takashi Miura, Shun Nakaji

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: The purpose of this study was to investigate the efficacy of carperitide (human atrial natriuretic peptide [h-ANP]) in perioperative management in patients with renal dysfunction, especially its kidney-protecting effects. Patients and Methods: The subjects were 18 patients who underwent elective cardiac surgery using cardiopulmonary bypass (CPB) with a preoperative serum creatinine (Cr) level of 1.2 mg/dl or more. The subjects were prospectively assigned to 2 groups: an h-ANPtreated group (Group H, n = 10) and a non-h-ANP-treated group (Group N, n = 8). At the beginning of surgery, h-ANP administration was initiated and continued for 5 days or more. The central dose was 0.02 μ;/kg/min. The primary end point included the serum Cr level and creatinine clearance (Ccr). Results: In Group H, Cr level significantly decreased after surgery compared to the preoperative level. The Ccr values were significantly higher 2 and 3 days after surgery than the preoperative values. And the intraoperative urine volume significantly increased. In Group H, an increase in urinary N-acetyl-beta-D-glucosaminidase (NAG) level the day after surgery was significantly inhibited in comparison with Group N. Conclusion: The results of this study suggest that in patients with renal dysfunction before cardiac surgery, continuous low-dose h-ANP therapy maintains renal function, preventing its deterioration. (Ann Thorac Cardiovasc Surg 2008; 14: 294-302).

Original languageEnglish (US)
Pages (from-to)294-302
Number of pages9
JournalAnnals of Thoracic and Cardiovascular Surgery
Volume14
Issue number5
StatePublished - Oct 1 2008

Fingerprint

Atrial Natriuretic Factor
Thoracic Surgery
Creatinine
Kidney
Ambulatory Surgical Procedures
Acetylglucosaminidase
Serum
Cardiopulmonary Bypass
Urine

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Gastroenterology

Cite this

Izumi, Kenta ; Eishi, Kiyoyuki ; Yamachika, Shiro ; Hashizume, Kouji ; Tada, Seiichi ; Yamane, Kentaro ; Takai, Hideaki ; Tanigawa, Kazuyoshi ; Miura, Takashi ; Nakaji, Shun. / The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery. In: Annals of Thoracic and Cardiovascular Surgery. 2008 ; Vol. 14, No. 5. pp. 294-302.
@article{61ebedd1b9894d26b9e3ffe2f96bce6d,
title = "The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery",
abstract = "Objectives: The purpose of this study was to investigate the efficacy of carperitide (human atrial natriuretic peptide [h-ANP]) in perioperative management in patients with renal dysfunction, especially its kidney-protecting effects. Patients and Methods: The subjects were 18 patients who underwent elective cardiac surgery using cardiopulmonary bypass (CPB) with a preoperative serum creatinine (Cr) level of 1.2 mg/dl or more. The subjects were prospectively assigned to 2 groups: an h-ANPtreated group (Group H, n = 10) and a non-h-ANP-treated group (Group N, n = 8). At the beginning of surgery, h-ANP administration was initiated and continued for 5 days or more. The central dose was 0.02 μ;/kg/min. The primary end point included the serum Cr level and creatinine clearance (Ccr). Results: In Group H, Cr level significantly decreased after surgery compared to the preoperative level. The Ccr values were significantly higher 2 and 3 days after surgery than the preoperative values. And the intraoperative urine volume significantly increased. In Group H, an increase in urinary N-acetyl-beta-D-glucosaminidase (NAG) level the day after surgery was significantly inhibited in comparison with Group N. Conclusion: The results of this study suggest that in patients with renal dysfunction before cardiac surgery, continuous low-dose h-ANP therapy maintains renal function, preventing its deterioration. (Ann Thorac Cardiovasc Surg 2008; 14: 294-302).",
author = "Kenta Izumi and Kiyoyuki Eishi and Shiro Yamachika and Kouji Hashizume and Seiichi Tada and Kentaro Yamane and Hideaki Takai and Kazuyoshi Tanigawa and Takashi Miura and Shun Nakaji",
year = "2008",
month = "10",
day = "1",
language = "English (US)",
volume = "14",
pages = "294--302",
journal = "Annals of Thoracic and Cardiovascular Surgery",
issn = "1341-1098",
publisher = "Japanese Association for Coronary Artery Surgery",
number = "5",

}

Izumi, K, Eishi, K, Yamachika, S, Hashizume, K, Tada, S, Yamane, K, Takai, H, Tanigawa, K, Miura, T & Nakaji, S 2008, 'The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery', Annals of Thoracic and Cardiovascular Surgery, vol. 14, no. 5, pp. 294-302.

The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery. / Izumi, Kenta; Eishi, Kiyoyuki; Yamachika, Shiro; Hashizume, Kouji; Tada, Seiichi; Yamane, Kentaro; Takai, Hideaki; Tanigawa, Kazuyoshi; Miura, Takashi; Nakaji, Shun.

In: Annals of Thoracic and Cardiovascular Surgery, Vol. 14, No. 5, 01.10.2008, p. 294-302.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery

AU - Izumi, Kenta

AU - Eishi, Kiyoyuki

AU - Yamachika, Shiro

AU - Hashizume, Kouji

AU - Tada, Seiichi

AU - Yamane, Kentaro

AU - Takai, Hideaki

AU - Tanigawa, Kazuyoshi

AU - Miura, Takashi

AU - Nakaji, Shun

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Objectives: The purpose of this study was to investigate the efficacy of carperitide (human atrial natriuretic peptide [h-ANP]) in perioperative management in patients with renal dysfunction, especially its kidney-protecting effects. Patients and Methods: The subjects were 18 patients who underwent elective cardiac surgery using cardiopulmonary bypass (CPB) with a preoperative serum creatinine (Cr) level of 1.2 mg/dl or more. The subjects were prospectively assigned to 2 groups: an h-ANPtreated group (Group H, n = 10) and a non-h-ANP-treated group (Group N, n = 8). At the beginning of surgery, h-ANP administration was initiated and continued for 5 days or more. The central dose was 0.02 μ;/kg/min. The primary end point included the serum Cr level and creatinine clearance (Ccr). Results: In Group H, Cr level significantly decreased after surgery compared to the preoperative level. The Ccr values were significantly higher 2 and 3 days after surgery than the preoperative values. And the intraoperative urine volume significantly increased. In Group H, an increase in urinary N-acetyl-beta-D-glucosaminidase (NAG) level the day after surgery was significantly inhibited in comparison with Group N. Conclusion: The results of this study suggest that in patients with renal dysfunction before cardiac surgery, continuous low-dose h-ANP therapy maintains renal function, preventing its deterioration. (Ann Thorac Cardiovasc Surg 2008; 14: 294-302).

AB - Objectives: The purpose of this study was to investigate the efficacy of carperitide (human atrial natriuretic peptide [h-ANP]) in perioperative management in patients with renal dysfunction, especially its kidney-protecting effects. Patients and Methods: The subjects were 18 patients who underwent elective cardiac surgery using cardiopulmonary bypass (CPB) with a preoperative serum creatinine (Cr) level of 1.2 mg/dl or more. The subjects were prospectively assigned to 2 groups: an h-ANPtreated group (Group H, n = 10) and a non-h-ANP-treated group (Group N, n = 8). At the beginning of surgery, h-ANP administration was initiated and continued for 5 days or more. The central dose was 0.02 μ;/kg/min. The primary end point included the serum Cr level and creatinine clearance (Ccr). Results: In Group H, Cr level significantly decreased after surgery compared to the preoperative level. The Ccr values were significantly higher 2 and 3 days after surgery than the preoperative values. And the intraoperative urine volume significantly increased. In Group H, an increase in urinary N-acetyl-beta-D-glucosaminidase (NAG) level the day after surgery was significantly inhibited in comparison with Group N. Conclusion: The results of this study suggest that in patients with renal dysfunction before cardiac surgery, continuous low-dose h-ANP therapy maintains renal function, preventing its deterioration. (Ann Thorac Cardiovasc Surg 2008; 14: 294-302).

UR - http://www.scopus.com/inward/record.url?scp=58749094799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58749094799&partnerID=8YFLogxK

M3 - Article

C2 - 18989245

AN - SCOPUS:58749094799

VL - 14

SP - 294

EP - 302

JO - Annals of Thoracic and Cardiovascular Surgery

JF - Annals of Thoracic and Cardiovascular Surgery

SN - 1341-1098

IS - 5

ER -